FLC
CNTB

Fifth Lane Capital’s Connect Biopharma Holdings CNTB Stock Holding History

Fifth Lane Capital’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Buy
+45,000
New +$117K 0.14% 50

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Fifth Lane Capital's CNTB Position: Q1 2026 in Review

Fifth Lane Capital opened a new position in Connect Biopharma Holdings (CNTB) in Q1 2026: 45,000 shares worth $118K. The stake represents 0.14% of the portfolio and ranks #50 among its holdings.

41 funds tracked by Wall St. Rank hold CNTB as of Q1 2026.

  • Fifth Lane Capital held 45,000 shares of Connect Biopharma Holdings worth $118K as of Q1 2026.
  • Connect Biopharma Holdings was a new Fifth Lane Capital position in Q1 2026.
  • Connect Biopharma Holdings made up 0.14% of Fifth Lane Capital's portfolio in Q1 2026, its #50 holding.
  • 41 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2026.

Based on Fifth Lane Capital's 13F filing for Q1 2026, filed 15 May 2026.